Immuneering Corporation (IMRX) Stock Analysis & Investment Frameworks
Immuneering Corporation (IMRX) stock analysis on Invetso. Review Immuneering Corporation’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Immuneering Corporation Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Immuneering Corporation Key Financial Metrics
- Market Cap: $228.61M
- Revenue: $N/A
- ROE: -33.91%
- ROIC: -42.90%
- Dividend Yield: N/A
About Immuneering Corporation
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.
Immuneering Corporation Investment Frameworks
Invetso analyzes Immuneering Corporation (IMRX) across the following frameworks:
- Immuneering Corporation 10Y Growth Potential
- Immuneering Corporation Scenario Analysis
- Immuneering Corporation Risks & Opportunities
- Immuneering Corporation Economic Moat
- Immuneering Corporation Business Model
- Immuneering Corporation Management
- Immuneering Corporation SWOT Analysis
- Immuneering Corporation Porter's 5 Forces
- Immuneering Corporation PESTLE Analysis
- Immuneering Corporation ESG Analysis